TITLE

Pharma: Clinic Roundup

PUB. DATE
May 2013
SOURCE
BioWorld Today;5/13/2013, Vol. 24 Issue 91, p9
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports that Eli Lilly and Co. of Indianapolis, Indiana will stop development of enzastaurin, a monotherapy in preventing relapse in patients with diffuse large B-cell lymphoma, based on findings of Phase III PRELUDE study of enzastaurin.
ACCESSION #
87593107

 

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics